2. Immunology/Inflammation Apoptosis
  3. COX Apoptosis
  4. Ketorolac hemicalcium

Ketorolac hemicalcium  (Synonyms: RS37619 hemicalcium)

Cat. No.: HY-B0580C
Handling Instructions

Molarity Calculator

Ketorolac (RS37619) hemicalcium is a non-steroidal anti-inflammatory drug (NSAID), acting as a nonselective COX inhibitor, with IC50s of 20 nM for COX-1 and 120 nM for COX-2. Ketorolac tromethamine is used as 0.5% ophthalmic solution for the research of allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain. Ketorola chemicalcium is also a DDX3 inhibitor that can be used for cancer research.

For research use only. We do not sell to patients.

Ketorolac hemicalcium Chemical Structure

Ketorolac hemicalcium Chemical Structure

CAS No. : 167105-81-9

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Ketorolac hemicalcium:

Other Forms of Ketorolac hemicalcium:

Ketorolac hemicalcium Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Ketorolac hemicalcium

View All COX Isoform Specific Products:

View All Isoforms
COX COX-1 COX-2 COX-3

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Ketorolac (RS37619) hemicalcium is a non-steroidal anti-inflammatory drug (NSAID), acting as a nonselective COX inhibitor, with IC50s of 20 nM for COX-1 and 120 nM for COX-2. Ketorolac tromethamine is used as 0.5% ophthalmic solution for the research of allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain. Ketorola chemicalcium is also a DDX3 inhibitor that can be used for cancer research[1][4].

In Vitro

Ketorolac (RS37619) salt (0-30 μM; 48 h) effectively kills the oral cancer cells[4].
Ketorolac salt (0-5 μM; 48 h) inhibits the expression of DDX3 protein, and induces apoptosis in H357 cells[4].
Ketorolac salt (0-2.5 μM; 0-16 h) inhibits the proliferation of oral cancer cells[4].
Ketorolac salt (0-50 μM) directly interacts with DDX3 and inhibits the ATPase activity[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ketorolac hemicalcium Related Antibodies

Cell Viability Assay[4]

Cell Line: HOK, SCC4, SCC9 and H357 cells
Concentration: 0-30 μM
Incubation Time: 48 h
Result: Showed inhibition with IC50s of 2.6, 7.1 and 8.1 μM against H357, SCC4 and SCC9 cells, respectively. And the normal HOK cell line did not show any cell death effect.

Cell Proliferation Assay[4]

Cell Line: H357
Concentration: 0.5, 1.0, 1.5, 2.0 and 2.5 μM
Incubation Time: 0, 8 and 16 h
Result: Inhibited the proliferation.

Western Blot Analysis[4]

Cell Line: H357
Concentration: 1, 2.5 and 5 μM
Incubation Time: 48 h
Result: Significantly reduced DDX3 protein expression levels, but not completely ablated as compared to DMSO treated cells. Up regulated the expression of E-cadherin.

Apoptosis Analysis[4]

Cell Line: H357
Concentration: 2.5 and 5 μM
Incubation Time: 48 h
Result: Induced apoptosis.
In Vivo

Ketorolac (RS37619) (0.4% ketorolac tromethamine ophthalmic solution) shows powerful ocular anti-inflammatory activities in rabbits[1].
Ketorolac (4 mg/kg/day, p.o.; 2 weeks) has no detrimental effect in the volume fraction of bone trabeculae formed inside the alveolar socket in rats[2].
Ketorolac (60 μg; intrathecal injection; once) attenuates the damage caused by spinal cord ischemia in rats[3].
Ketorolac salt (20 and 30 mg/kg; i.p.; two times in a week for 3 weeks) reduces oral carcinogenesis in mice[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: New Zealand White rabbits (2.0–2.7 kg), LPS endotoxin-induced ocular inflammation[1]
Dosage: 50 μL ketorolac tromethamine ophthalmic solution 0.4%
Administration: In eyes, twice, 2 hours and 1 hour before LPS challenge
Result: Resulted in a nearly complete inhibition (98.7%) of LPS endotoxin-induced increases in FITC (fluorescein isothiocyanate)-dextran in the anterior chamber, and resulted in a nearly complete inhibition (97.5%) of LPS endotoxin-induced increases in aqueous PGE2 concentrations in the aqueous humor.
Animal Model: Male Wistar rats (400–450 g), spinal cord ischemia model[3]
Dosage: 30 and 60 μg
Administration: Intrathecal injection, 1 h before the ischemia induction for once
Result: Significantly reduced the motor disturbances and improved the survival rate at 60 μg.
Animal Model: BALB/c mice, oral carcinogenesis model[4]
Dosage: 20 mg/kg and 30 mg/kg
Administration: IP injection, two times in a week for 3 weeks
Result: Decreased tumor burden, reduced expression of DDX3 and anti-apoptotic proteins (Bcl-2 and Mcl-1).
Clinical Trial
Molecular Weight

274.31

Formula

C15H12CaNO3+
CAS No.
SMILES

O=C(C1C2=CC=C(C(C3=CC=CC=C3)=O)N2CC1)[O-].[Ca+2].[0.5]
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Ketorolac hemicalcium Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Ketorolac hemicalcium167105-81-9RS37619 hemicalciumCOXApoptosisCyclooxygenaseallergic conjunctivitiscystoid macular edemaintraoperative miosispostoperative ocularinflammationophthalmic solutionnon-steroidal anti-inflammatory drugNSAIDovarian canceranticanceroral cancerInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Ketorolac hemicalcium
Cat. No.:
HY-B0580C
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (0 KB) Français - FR (0 KB) Deutsch - DE (0 KB) Norwegian - NO (0 KB) Español - ES (0 KB) Swedish - SV (0 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.